Clinical Trial Update: Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating Quaratusugene Ozeplasmid (Reqorsa) in combination with Osimertinib for advanced non-small cell lung cancer in patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Reqorsa (Quaratusugene ozeplasmid)

Snippet

Sponsor: Genprex, Inc. | Conditions: Carcinoma, Non-Small Cell Lung | Phase 1, Phase 2 | Status: RECRUITING